Sobi

Swedish Orphan Biovitrum AB is engaged in the development, marketing, and distribution of orphan products and specialty pharmaceuticals. The company provides treatments for rare and life-threatening diseases, such as those in cardiology, conditions affecting immunocompromised patients, genetic disorders, hematology, infectious diseases, metabolic disorders, oncology, palliative care, toxicology control, respiratory diseases, and urological conditions. In 2009, Swedish Orphan International merged with Biovitrum, and the combined company was subsequently renamed Swedish Orphan Biovitrum. The company’s products are sold in Europe, North America, and Japan, with its headquarters located in Stockholm, Sweden.